A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
CONCLUSION: A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated combination are comparable to other contemporary approved triplet combinations.PMID:37127471 | DOI:10.1016/j.clml.2023.03.016 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Manisha Bhutani David M Foureau Myra Robinson Fei Guo Kateryna Fesenkova Shebli Atrash Barry Paul Cindy Varga Reed Friend Mauricio Pineda-Roman Katherine Rigby James T Symanowski Sarah Norek Mallory R Tucker Lawrence J Druhan Peter M Voorhees Saad Z Usman Source Type: research
Autologous Stem Cell Transplant in Lymphoma Using a Noncryopreserved Platform: An Adapted Sequential Conditioning Maintaining Dose Intensity Does not Affect Transplantation Outcomes
CONCLUSION: In conclusion, conditioning adjusted for a noncryopreserved strategy offers at least similar or even better results than the cryopreserved strategy. Prospective studies are warranted.PMID:37127472 | DOI:10.1016/j.clml.2023.04.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Mauricio Sarmiento Patricio Rojas Catherine Gutierrez Jacqueline Quezada Veronica Jara James Campbell Garcia Maria None Jose None VicenteSandoval Max Vergara Nicolas Triantafilo Mauricio Ocqueteau Source Type: research
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
CONCLUSION: This is the first formal prospective trial using infusion times shorter than the standard schedule directly after an initial 4-hours dose. This rapid infusion protocol has resulted in more efficient resource utilization and has become the standard protocol for the use in all intravenous daratumumab regimens in Canada. This approach has been particularly helpful in shortening chair time during the COVID-19 pandemic and providing a useful alternative in jurisdictions without access to subcutaneous daratumumab.PMID:37127473 | DOI:10.1016/j.clml.2023.03.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Julie Stakiw Shruthi Kodad Richard LeBlanc Michael Sebag Annette E Hay Vishal Kukreti Julie C ôté Fernando Camacho Molei Fu Engin Gul Donna Reece Source Type: research
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
CONCLUSION: A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated combination are comparable to other contemporary approved triplet combinations.PMID:37127471 | DOI:10.1016/j.clml.2023.03.016 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Manisha Bhutani David M Foureau Myra Robinson Fei Guo Kateryna Fesenkova Shebli Atrash Barry Paul Cindy Varga Reed Friend Mauricio Pineda-Roman Katherine Rigby James T Symanowski Sarah Norek Mallory R Tucker Lawrence J Druhan Peter M Voorhees Saad Z Usman Source Type: research
Autologous Stem Cell Transplant in Lymphoma Using a Noncryopreserved Platform: An Adapted Sequential Conditioning Maintaining Dose Intensity Does not Affect Transplantation Outcomes
CONCLUSION: In conclusion, conditioning adjusted for a noncryopreserved strategy offers at least similar or even better results than the cryopreserved strategy. Prospective studies are warranted.PMID:37127472 | DOI:10.1016/j.clml.2023.04.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Mauricio Sarmiento Patricio Rojas Catherine Gutierrez Jacqueline Quezada Veronica Jara James Campbell Garcia Maria None Jose None VicenteSandoval Max Vergara Nicolas Triantafilo Mauricio Ocqueteau Source Type: research
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
CONCLUSION: This is the first formal prospective trial using infusion times shorter than the standard schedule directly after an initial 4-hours dose. This rapid infusion protocol has resulted in more efficient resource utilization and has become the standard protocol for the use in all intravenous daratumumab regimens in Canada. This approach has been particularly helpful in shortening chair time during the COVID-19 pandemic and providing a useful alternative in jurisdictions without access to subcutaneous daratumumab.PMID:37127473 | DOI:10.1016/j.clml.2023.03.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Julie Stakiw Shruthi Kodad Richard LeBlanc Michael Sebag Annette E Hay Vishal Kukreti Julie C ôté Fernando Camacho Molei Fu Engin Gul Donna Reece Source Type: research
Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States
Clin Lymphoma Myeloma Leuk. 2023 Mar 30:S2152-2650(23)00112-X. doi: 10.1016/j.clml.2023.03.015. Online ahead of print.ABSTRACTIn newly diagnosed stage III/IV classic Hodgkin lymphoma (cHL), A+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) improved overall survival (OS) versus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). As clinical trial and real-world populations may differ, real-world treatment characteristics and OS (rwOS) were assessed for patients with stage III/IV cHL treated with frontline ABVD. This retrospective, observational analysis of deidentified electronic health record data (1/...
Source: Clinical Lymphoma and Myeloma - April 30, 2023 Category: Cancer & Oncology Authors: Allison Winter Nicholas Liu Andy Surinach Michelle Fanale Kristina S Yu Mayur Narkhede Source Type: research
Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States
Clin Lymphoma Myeloma Leuk. 2023 Mar 30:S2152-2650(23)00112-X. doi: 10.1016/j.clml.2023.03.015. Online ahead of print.ABSTRACTIn newly diagnosed stage III/IV classic Hodgkin lymphoma (cHL), A+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) improved overall survival (OS) versus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). As clinical trial and real-world populations may differ, real-world treatment characteristics and OS (rwOS) were assessed for patients with stage III/IV cHL treated with frontline ABVD. This retrospective, observational analysis of deidentified electronic health record data (1/...
Source: Clinical Lymphoma and Myeloma - April 30, 2023 Category: Cancer & Oncology Authors: Allison Winter Nicholas Liu Andy Surinach Michelle Fanale Kristina S Yu Mayur Narkhede Source Type: research
Association of KIR Genes Polymorphism and its HLA Ligands in Diffuse Large B-cell Lymphoma
CONCLUSION: With this, we can conclude that the polymorphism of KIR genes and the association with HLA ligands can influence the prognosis of DLBCL, as well as the response to treatment was found. With this, we can conclude that the polymorphism of KIR genes and the association with HLA ligands can influence the prognosis of DLBCL, as well as the response to treatment.Non-Hodgkin lymphoma (NHL) is a heterogeneous disease, with each subtype associated with different risk factors. Within this group, diffuse large B-cell lymphoma (DLBCL) can be highlighted, the most common type of NHL.NK cells are key components of the innate...
Source: Clinical Lymphoma and Myeloma - April 27, 2023 Category: Cancer & Oncology Authors: Cardozo Daniela Maira Marangon Amanda Vansan Guimar ães Fernando Marques Silvia Lieber Sofia Delamain M árcia Aranha Francisco Jos é Penteado Visentainer Jeane Eliete Laguila de Souza C ármino Antonio Source Type: research
Association of KIR Genes Polymorphism and its HLA Ligands in Diffuse Large B-cell Lymphoma
CONCLUSION: With this, we can conclude that the polymorphism of KIR genes and the association with HLA ligands can influence the prognosis of DLBCL, as well as the response to treatment was found. With this, we can conclude that the polymorphism of KIR genes and the association with HLA ligands can influence the prognosis of DLBCL, as well as the response to treatment.Non-Hodgkin lymphoma (NHL) is a heterogeneous disease, with each subtype associated with different risk factors. Within this group, diffuse large B-cell lymphoma (DLBCL) can be highlighted, the most common type of NHL.NK cells are key components of the innate...
Source: Clinical Lymphoma and Myeloma - April 27, 2023 Category: Cancer & Oncology Authors: Cardozo Daniela Maira Marangon Amanda Vansan Guimar ães Fernando Marques Silvia Lieber Sofia Delamain M árcia Aranha Francisco Jos é Penteado Visentainer Jeane Eliete Laguila de Souza C ármino Antonio Source Type: research
Association of KIR Genes Polymorphism and its HLA Ligands in Diffuse Large B-cell Lymphoma
CONCLUSION: With this, we can conclude that the polymorphism of KIR genes and the association with HLA ligands can influence the prognosis of DLBCL, as well as the response to treatment was found. With this, we can conclude that the polymorphism of KIR genes and the association with HLA ligands can influence the prognosis of DLBCL, as well as the response to treatment.Non-Hodgkin lymphoma (NHL) is a heterogeneous disease, with each subtype associated with different risk factors. Within this group, diffuse large B-cell lymphoma (DLBCL) can be highlighted, the most common type of NHL.NK cells are key components of the innate...
Source: Clinical Lymphoma and Myeloma - April 27, 2023 Category: Cancer & Oncology Authors: Cardozo Daniela Maira Marangon Amanda Vansan Guimar ães Fernando Marques Silvia Lieber Sofia Delamain M árcia Aranha Francisco Jos é Penteado Visentainer Jeane Eliete Laguila de Souza C ármino Antonio Source Type: research
Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study
CONCLUSION: To our knowledge, this is the first study of its kind to establish a suite of consumer-endorsed PROMs for use in clinical trials in patients with MM. Ensuring that the patient voice is at the center of advances in cancer treatment is a hallmark of quality cancer care.PMID:37087351 | DOI:10.1016/j.clml.2023.03.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 22, 2023 Category: Cancer & Oncology Authors: Hayley Beer Holly Chung Simon J Harrison Hang Quach Rebecca Taylor-Marshall Laura Jones Meinir Krishnasamy Source Type: research
Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study
CONCLUSION: To our knowledge, this is the first study of its kind to establish a suite of consumer-endorsed PROMs for use in clinical trials in patients with MM. Ensuring that the patient voice is at the center of advances in cancer treatment is a hallmark of quality cancer care.PMID:37087351 | DOI:10.1016/j.clml.2023.03.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 22, 2023 Category: Cancer & Oncology Authors: Hayley Beer Holly Chung Simon J Harrison Hang Quach Rebecca Taylor-Marshall Laura Jones Meinir Krishnasamy Source Type: research
Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study
CONCLUSION: To our knowledge, this is the first study of its kind to establish a suite of consumer-endorsed PROMs for use in clinical trials in patients with MM. Ensuring that the patient voice is at the center of advances in cancer treatment is a hallmark of quality cancer care.PMID:37087351 | DOI:10.1016/j.clml.2023.03.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 22, 2023 Category: Cancer & Oncology Authors: Hayley Beer Holly Chung Simon J Harrison Hang Quach Rebecca Taylor-Marshall Laura Jones Meinir Krishnasamy Source Type: research
Progression of Hodgkin lymphoma and plasma cell neoplasms: Report from the 2021 SH/EAHP Workshop
CONCLUSIONS: Better molecular characterization of both of these neoplasms and mechanisms of progression will help us to better understand mechanisms of progression and perhaps develop better prognostic models, as well as identifying novel therapeutic targets.PMID:37085150 | DOI:10.1093/ajcp/aqad023 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 21, 2023 Category: Cancer & Oncology Authors: Reza Nejati Catalina Amador Magdalena Czader Elizabeth Thacker Devang Thakkar Sandeep S Dave Ahmet Dogan Amy Duffield John R Goodlad German Ott Mariusz A Wasik Wenbin Xiao James R Cook Source Type: research
